Ratings by Ladenburg Thalmann (Kevin DeGeeter)

Date CompanySymbol Type Rating
(Past)
PT
(Past)
Start $
(End $)
% Chg. Details
7/1/2026 Compass Therapeutics CMPX New Coverage Buy
(N/A)
2.19
(2.05)
-6.39% Details
6/18/2026 Elicio Therapeutics ELTX New Coverage Buy
(N/A)
4.71
(3.11)
-33.97% Details
6/15/2026 Traws Pharma Inc. TRAW Downgrade Neutral
(Buy)
1.28
(0.67)
-47.66% Details
5/15/2026 Cellectar Biosciences CLRB New Coverage Buy
(N/A)
3.20
(2.51)
-21.56% Details
5/11/2026 UroGen Pharma URGN New Coverage Buy
(N/A)
29.40
(40.23)
36.84% Details
1/30/2026 Traws Pharma Inc. TRAW New Coverage Buy
(N/A)
2.10
(1.28)
-39.05% Details
1/23/2026 Decoy Therapeutics Inc. DCOY New Coverage Buy
(N/A)
0.75
(5.61)
648% Details
11/7/2025 NextCure Inc. NXTC Upgrade Buy
(Neutral)
9.82
(5.99)
-39% Details
10/31/2025 NovoCure Ltd. NVCR Maintain Buy
(N/A)
 
 
  Details
7/8/2025 ORIC Pharmaceuticals ORIC New Coverage Buy
(N/A)
10.65
(10.73)
0.75% Details
7/8/2025 Opko Health OPK New Coverage Buy
(N/A)
1.34
(1.19)
-11.19% Details
7/8/2025 NovoCure Ltd. NVCR New Coverage Buy
(N/A)
16.89
(15.92)
-5.74% Details
7/8/2025 NextCure Inc. nxtc New Coverage Neutral
(N/A)
0.44
(9.82)
2131.82% Details
7/8/2025 Cardiff Oncology CRDF New Coverage Buy
(N/A)
3.65
(0.88)
-75.89% Details
7/20/2022 Invitae Corporation NVTA Downgrade
(Buy)
2.21
(0.02)
-99.1% Details
2/18/2021 Invitae Corporation NVTA Upgrade Buy
(Neutral)
47.86
(0.02)
-99.96% Details
8/5/2020 Invitae Corporation NVTA Maintain Buy
(N/A)
 
 
  Details
6/23/2020 Invitae Corporation NVTA Maintain Buy
(N/A)
 
 
  Details
5/13/2020 Cyclacel Pharmaceuticals CYCC Maintain Buy
(N/A)
 
 
  Details
5/6/2020 Invitae Corporation NVTA Maintain Buy
(N/A)
 
 
  Details
8/7/2019 Invitae Corporation NVTA Maintain Buy
(N/A)
 
 
  Details
7/12/2019 Invitae Corporation NVTA Maintain Buy
(N/A)
 
 
  Details
10/1/2018 Neon Therapeutics NTGN New Coverage Buy
(N/A)
8.40
(3.07)
-63.45% Details
9/20/2018 Invitae Corporation NVTA Maintain Buy
(N/A)
 
 
  Details
9/7/2018 Cyclacel Pharmaceuticals CYCC New Coverage Buy
(N/A)
1.48
(6.37)
330.41% Details
9/5/2018 Vericel Corporation VCEL Maintain Buy
(N/A)
 
 
  Details